Poseida Therapeutics, Inc. (PSTX)
NASDAQ: PSTX · Real-Time Price · USD
2.530
+0.060 (2.43%)
Nov 4, 2024, 4:00 PM EST - Market closed
Poseida Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for PSTX stock have an average target of 15, with a low estimate of 10 and a high estimate of 20. The average target predicts an increase of 492.89% from the current stock price of 2.53.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for PSTX stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +690.51% | Oct 30, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +690.51% | Oct 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +690.51% | Aug 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +690.51% | Jul 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +690.51% | May 22, 2024 |
Financial Forecast
Revenue This Year
88.34M
from 64.70M
Increased by 36.53%
Revenue Next Year
44.20M
from 88.34M
Decreased by -49.96%
EPS This Year
-1.44
from -1.37
EPS Next Year
-1.87
from -1.44
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 96.2M | 73.5M | 46.2M | ||
| Avg | 88.3M | 44.2M | 22.4M | ||
| Low | 82.4M | 9.8M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 48.6% | -16.8% | 4.5% | ||
| Avg | 36.5% | -50.0% | -49.2% | ||
| Low | 27.4% | -88.9% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.31 | -1.51 | -1.13 | ||
| Avg | -1.44 | -1.87 | -1.49 | ||
| Low | -1.54 | -2.33 | -1.80 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.